Australia - English - Department of Health (Therapeutic Goods Administration)

stallergenes australia pty ltd - lolium perenne, quantity: 20 %; phleum pratense, quantity: 20 %; anthoxanthum odoratum, quantity: 20 %; dactylis glomerata, quantity: 20 %; poa pratensis, quantity: 20 % - tablet - excipient ingredients: croscarmellose sodium; colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; lactose monohydrate - treatment of grass pollen allergic rhinitis with or without conjunctivitis in adults, adolescents and children (above the age of 5) with clinically relevant symptoms, confirmed by a positive cutaneous test and/or a positive titre of the specific ige to the grass pollen.

Australia - English - Department of Health (Therapeutic Goods Administration)

stallergenes australia pty ltd - olea europaea, quantity: 10 ir/ml - injection, suspension - excipient ingredients: aluminium hydroxide hydrate; sodium chloride; mannitol; phenol; water for injections - treatment of patients with type 1 allergy (gell and coombs classification), particularly presenting as seasonal or perennial rhinitis, conjunctivitis, rhinoconjunctivitis, with or without associated asthma.

Australia - English - Department of Health (Therapeutic Goods Administration)

stallergenes australia pty ltd - european house dust mite extract, quantity: 5 ir/ml; american house dust mite extract, quantity: 5 ir/ml - injection, suspension - excipient ingredients: aluminium hydroxide hydrate; phenol; sodium chloride; water for injections; mannitol - treatment of patients with type 1 allergy (gell and coombs classification), particularly presenting as seasonal or perennial rhinitis, conjunctivitis, rhinoconjunctivitis, with or without associated asthma.

Australia - English - Department of Health (Therapeutic Goods Administration)

stallergenes australia pty ltd - xanthium strumarium, quantity: 0.11 ml/ml (equivalent: xanthium strumarium, qty 11 mg/ml); chenopodium album, quantity: 0.11 ml/ml (equivalent: chenopodium album, qty 11 mg/ml); iva axillaris, quantity: 0.04 ml/ml (equivalent: iva axillaris, qty 4 mg/ml); amaranthus retroflexus, quantity: 0.11 ml/ml (equivalent: amaranthus retroflexus, qty 11 mg/ml); salsola kali, quantity: 0.11 ml/ml (equivalent: salsola kali, qty 11 mg/ml); artemisia tridentata, quantity: 0.03 ml/ml (equivalent: artemisia tridentata, qty - extract, liquid - excipient ingredients: glycerol; sodium chloride; sodium bicarbonate; water for injections - indicated use of allergenic extracts is for the diagnosis and treatment (hypo-sensitization therapy) of patients who experience allergic symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

stallergenes australia pty ltd - chenopodium album, quantity: 1 ml/ml (equivalent: chenopodium album, qty 50 mg/ml) - extract, liquid - excipient ingredients: glycerol; sodium chloride; sodium bicarbonate; water for injections - indicated use of allergenic extracts is for the diagnosis and treatment (hypo-sensitization therapy) of patients who experience allergic symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

stallergenes australia pty ltd - ambrosia artemisiifolia, quantity: 0.25 ml/ml (equivalent: ambrosia artemisiifolia, qty 12 mg/ml); ambrosia psilostachya, quantity: 0.25 ml/ml (equivalent: ambrosia psilostachya, qty 12 mg/ml) - extract, liquid - excipient ingredients: glycerol; sodium chloride; sodium bicarbonate; water for injections - indicated use of allergenic extracts is for the diagnosis and treatment (hypo-sensitization therapy) of patients who experience allergic symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

stallergenes australia pty ltd - rumex crispus, quantity: 0.5 ml/ml (equivalent: rumex crispus, qty 25 mg/ml); rumex acetosella, quantity: 0.5 ml/ml (equivalent: rumex acetosella, qty 25 mg/ml) - extract, liquid - excipient ingredients: glycerol; sodium chloride; sodium bicarbonate; water for injections - indicated use of allergenic extracts is for the diagnosis and treatment (hypo-sensitization therapy) of patients who experience allergic symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

stallergenes australia pty ltd - plantago lanceolata, quantity: 1 ml/ml (equivalent: plantago lanceolata, qty 50 mg/ml) - extract, liquid - excipient ingredients: glycerol; sodium chloride; sodium bicarbonate; water for injections - indicated use of allergenic extracts is for the diagnosis and treatment (hypo-sensitization therapy) of patients who experience allergic symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

stallergenes australia pty ltd - ligustrum vulgare, quantity: 1 ml/ml (equivalent: ligustrum vulgare, qty 50 mg/ml) - extract, liquid - excipient ingredients: glycerol; sodium chloride; sodium bicarbonate; water for injections - indicated use of allergenic extracts is for the diagnosis and treatment (hypo-sensitization therapy) of patients who experience allergic symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

stallergenes australia pty ltd - eucalyptus globulus, quantity: 1 ml/ml (equivalent: eucalyptus globulus, qty 50 mg/ml) - extract, liquid - excipient ingredients: glycerol; sodium chloride; sodium bicarbonate; water for injections - indicated use of allergenic extracts is for the diagnosis and treatment (hypo-sensitization therapy) of patients who experience allergic symptoms.